Aims: Left atrial appendage (LAA) closure is considered an effective option in patients with non-valvular atrial fibrillation (NVAF) and contraindications to long-term oral anticoagulant (OAC) therapy. However, there are some concerns about safety of currently available devices. Our aim is to provide an initial assessment on feasibility and safety of the novel LAA closure Ultraseal device in patients with NVAF and contraindications to long-term OAC therapy.
guidelines for the management of AF recommend to consider LAA closure in patients with a high stroke risk and contraindications for long-term OAC therapy (class of recommendation IIb, level of evidence B). 4 At this point in time, several devices for LAA closure have been developed and are widely used in clinical practice. 5, 6 The Ultraseal device (CARDIA Inc., Eagan, MI) is a novel LAA occlusion device that conforms to LAA anatomy.
The aim of this study is to provide an initial assessment of the feasibility and safety profile of the novel LAA closure Ultraseal device in patients with non-valvular AF and contraindications to long-term OAC therapy. All clinical and imaging baseline, periprocedural and follow-up data were prospectively entered in a dedicated database.
| Device features
The Ultraseal device is a fully retrievable and repositionable selfexpandable nitinol device composed by a distal soft bulb, that takes advantage of 12 stabilizing hooks to anchors the device to the LAA, and by proximal 3-leaflet sail covered by a polyvinyl alcohol foam for LAA occlusion. It takes advantage from a jointed technology that allows multidirectional movements and adjustment to different ostium angles and LAA shapes, and limits pressure on the tissue. Moreover, it can be pulled back and redeployed multiple times in the same delivery sheath.
The Cardia Delivery System includes the delivery forceps, the introducer and the delivery sheath. The flexible delivery forceps presents jaws allowing to hold and release the device at a grasping knob located at the center of the proximal sail, while a forceps handle locking mechanism prevents device detachment. The Cardia delivery sheath, ranging from 10 to 12 French, is currently available in a single (45°) and double (45°− 45°) curve preformed curves. 
| Device implantation
All procedures were performed under general anaesthesia, with TEE and fluoroscopy guidance. Femoral vein was the access site in all patients. Trans-septal puncture (TSP) was performed using BRK1
trans-septal needle. Heparin was administered in all patients during the procedures, in order to maintain an activated clotting time (ACT) of 250-300 s. Device placement and stability were assessed by TEE and fluoroscopy before its release.
Antithrombotic therapy at discharge was prescribed according to patients' risk profile and physicians' preferences.
| Definitions and outcomes
The annual risk of stroke and of thromboembolic events were assessed with the CHA2DS2-VASc score. 7 The annual risk for major bleeding was assessed with the HAS-BLED score. 8 Major bleedings were defined as bleeding ≥ type-3a according to the Bleeding Academic
Research Consortium (BARC) classification. 9 Procedural success was defined as a successful Ultraseal device implantation with LAA closure without major peri-device residual leak, defined as the presence of colour jet >5 mm at TEE.
All adverse events, both during index hospitalization and at follow-up, are reported according to Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies. Table 1 .
All patients had a history of clinically relevant or major bleeding under anticoagulation therapy (BARC >2 = 12, BARC >3 = 9) or were at high-risk for bleeding (n = 12). All patients except one presented a HAS-BLED score >2. Preprocedural TEE data are reported in Table 2 .
| Procedural data
Procedural data and in-hospital adverse events rate are shown in Table 3 . LAA had chicken-wing morphology in 10 patients, two lobes in 4 patient (Figure 1 ), and a windsock (single-lobe) morphology in the remaining 9 patients. Four patients needed more than one attempt of device implantation during the same procedure. In the first patient, the second attempt was needed for repositioning the device, while in the second patient the chosen device (20 mm) did not match the correct size and it was changed for a device of smaller size (18 mm). In this case, the first device was retrieved without any complications. In the third patient, the device was not correctly deployed: the proximal sail did not remain fastened to the LAA ostium after release, while the distal bulb remained anchored to the proximal part of LAA. The final result was a LAA partial closure provided by the distal bulb, with the proximal sail fluttering in the left atrium. Importantly, there was evidence of very 
| Clinical outcomes
Clinical follow up at 45 days was available for all patients. In 22 out of 23 patients a longer follow-up was also available, with a mean of 166 ± 80 days. All patients, with the exception of the one who died during the index hospitalization, were alive at the time of last follow-up. No episodes of major or minor bleeding and of ischemic stroke were observed. All patients underwent a TEE at 30-45 days.
No thrombus was revealed by TEE in any patient and leaks were observed in the patients that did not achieve procedural success: in the first one ( Figure 3 Further studies with randomized design, larger sample size, and longer follow-up are mandatory to assess the safety and efficacy of this device in comparison with OAC therapy and other available devices.
| Study limitations
The present study has several limitations, mainly represented by the small sample size, its observational nature, the relatively short followup, and the lack of comparison with another device for LAA occlusion.
However, sharing early experiences with innovative technologies is extremely important and provides reassurance on safety and performance of novel devices in clinical use. Larger studies with extended follow-up are needed in order to assess the safety and efficacy of this novel and promising percutaneous system for LAA occlusion.
| CONCLUSIONS
Our results suggest that the Ultraseal device is a feasible option for LAA occlusion. Importantly, the learning curve was fast, principally due to its intuitive loading and implantation features, resulting in very low complication rates. Further studies with large sample size and prolonged follow-up are necessary to definitely assess the safety and efficacy of this novel device. 
